The pharmacokinetics of penicillin G and ampicillin are reviewed as they pertain to their potential use in in vitro therapy. (C) 
he molecular structure of the penicillins consists of a thiazolidine ring connected to a [3- 1actam ring attached to a side chain. The side chain determines many of the pharmacologic characteristics of a given penicillin. The presence of an amino group on the benzyl side chain distinguishes ampicillin from benzylpenicillin (penicillin G), which is one example of the many chemical variants of penicillin resulting from alterations of this side chain attached to the basic 6 amino-penicillinoic acid molecule.
Recently, the issue of the relative superiority of penicillin G vs. ampicillin for in utero therapy has been raised. Amstey and Gibbs wrote an editorial opinion stating that the "favorable pharmacokinetics of penicillin G and its narrower and specific spectrum make this a better choice for group B streptococcal (GBS) prophylaxis than ampicillin
This editorial opinion has stimulated a growing ambiguity about the peripartal use of ampicillin. The purpose of this review is to examine the key points of these contentions and, in so doing, clarify the issue of ampicillin vs. penicillin G for in utero therapy and GBS prophylaxis.
LITERATURE REVIEW
A review of the literature on penicillin G and ampicillin reveals a dearth of pharmacokinetic data on penicillin G in pregnant subjects and extensive data on ampicillin in such patients. [2] [3] [4] [5] [6] [7] [8] [9] A partial explanation emanates from the fact that penicillin G was widely used prior to the evolution of pharmacokinetics into a distinct discipline. When ampicillin was introduced in the early 1960s, pharmacokinetics was the "new kid on the block," thus having the benefit of investigation through these newly evolved scientific methods. Being the focus of attention in the literature, ampicillin came to be considered the [3- Ampicillin Pharmacokinetics In contrast to penicillin G, the pharmacokinetics of ampicillin have been studied thoroughly, z'8 '9 It has been established that pregnant women exhibit renal clearances and total body clearances that are about 50% greater than those under control conditions. These control studies were performed 3-12 months after delivery when normal menstruation had resumed and breast-feeding had ceased. The oral bioavailability was very similar during pregnancy and 3-12 months postpartum (approximately 50%), and the recovery of the drug in the urine was essentially unaffected by pregnancy. 6 
